|
[1]MOMENI M,ZAINODINI N,BIDAKI R,et al.Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients[J].Hum Immunol,2014,75(1):15-19.
|
|
[2]LIU S,PENG N,XIE J,et al.Human hepatitis B virus surface and e antigens inhibit major vault protein signaling in interferon induction pathways[J].J Hepatol,2015,62(5):1015-1023.
|
|
[3]FLETCHER SP,CHIN DJ,JI Y,et al.Transcriptomic analysis of the woodchuck model of chronic hepatitis B[J].Hepatology,2012,56(3):820-830.
|
|
[4]WIELAND S,THIMME R,PURCELL RH,et al.Genomic analysis of the host response to hepatitis B virus infection[J].Proc Natl Acad Sci U S A,2004,101(17):6669-6674.
|
|
[5]DICKSON I.Viral hepatitis:a lack of hepatocyte STING favours HBV infection[J].Nat Rev Gastroenterol Hepatol,2016,13(8):438.
|
|
[6]CHRISTEN V,DUONG F,BERNSMEIER C,et al.Inhibition of alpha interferon signaling by hepatitis B virus[J].J Virol,2007,81(1):159-165.
|
|
[7]BERTOLETTI A,FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.
|
|
[8]DECORSIERE A,MUELLER H,van BREUGEL PC,et al.Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J].Nature,2016,531(7594):386-389.
|
|
[9]MARTINET J,DUFEU-DUCHESNE T,BRUDER CJ,et al.Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection[J].Gastroenterology,2012,143(6):1586-1596.
|
|
[10]GHOSH S,NANDI M,PAL S,et al.Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection[J].Clin Microbiol Infect,2016.[Epub ahead of print]
|
|
[11]PALLETT LJ,GILL US,QUAGLIA A,et al.Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells[J].Nat Med,2015,21(6):591-600.
|
|
[12]XU X,SHANG Q,CHEN X,et al.Reversal of B-cell hyperactivation and functional impairment is associated with HBs Ag seroconversion in chronic hepatitis B patients[J].Cell Mol Immunol,2015,12(3):309-316.
|
|
[13]DAS A,ELLIS G,PALLANT C,et al.IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection[J].J Immunol,2012,189(8):3925-3935.
|
|
[14]BERTOLETTI A,MAINI MK,FERRARI C.The host-pathogen interaction during HBV infection:immunological controversies[J].Antivir Ther,2010,15(Suppl 3):15-24.
|
|
[15]BENGSCH B,MARTIN B,THIMME R.Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].J Hepatol,2014,61(6):1212-1219.
|
|
[16]BONI C,LAMPERTICO P,TALAMONA L,et al.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B[J].Hepatology,2015,62(6):1697-1709.
|
|
[17]KENNEDY PT,SANDALOVA E,JO J,et al.Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J].Gastroenterology,2012,143(3):637-645.
|
|
[18]SETO WK,CHAN TS,HWANG YY,et al.Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma:a prospective study[J].J Clin Oncol,2014,32(33):3736-3743.
|
|
[19]YAPALI S,TALAAT N,LOK AS.Management of hepatitis B:our practice and how it relates to the guidelines[J].Clin Gastroenterol Hepatol,2014,12(1):16-26.
|
|
[20]HADZIYANNIS SJ,SEVASTIANOS V,RAPTI I,et al.Sustained responses and loss of HBs Ag in HBe Ag-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J].Gastroenterology,2012,143(3):629-636.
|
|
[21]MELCHJORSEN J,RISOR MW,SOGAARD OS,et al.Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells[J].J Acquir Immune Defic Syndr,2011,57(4):265-275.
|
|
[22]WU ZG,YAN WM,GUO W,et al.Telbivudine preserves Thelper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis[J].J Viral Hepat,2010,17(Suppl 1):24-33.
|
|
[23]TAN AT,HOANG LT,CHIN D,et al.Reduction of HBV replication prolongs the early immunological response to IFNαtherapy[J].J Hepatol,2014,60(1):54-61.
|
|
[24]van der MOLEN RG,SPRENGERS D,BIESTA PJ,et al.Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV[J].Hepatology,2006,44(4):907-914.
|
|
[25]TJWA ET,van OORD GW,HEGMANS JP,et al.Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B[J].J Hepatol,2011,54(2):209-218.
|
|
[26]PEPPA D,MICCO L,JAVAID A,et al.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J].PLo S Pathog,2010,6(12):e1001227.
|
|
[27]TJWA ET,ZOUTENDIJK R,van OORD GW,et al.Similar frequencies,phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate(TDF)[J].Antiviral Res,2016,132:70-75.
|
|
[28]CHEN Y,LI X,YE B,et al.Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B[J].Antiviral Res,2011,91(1):23-31.
|
|
[29]BONI C,LACCABUE D,LAMPERTICO P,et al.Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues[J].Gastroenterology,2012,143(4):963-973.
|
|
[30]EVANS A,RIVA A,COOKSLEY H,et al.Programmed death 1expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion[J].Hepatology,2008,48(3):759-769.
|
|
[31]LI Y,MA S,TANG L,et al.Circulating chemokine(C-X-C Motif)receptor 5(+)CD4(+)T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection[J].Hepatology,2013,58(4):1277-1286.
|
|
[32]BONI C,PENNA A,BERTOLETTI A,et al.Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B[J].J Hepatol,2003,39(4):595-605.
|
|
[33]BONI C,PENNA A,OGG GS,et al.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy[J].Hepatology,2001,33(4):963-971.
|
|
[34]PEPPA D,GILL US,REYNOLDS G,et al.Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J].J Exp Med,2013,210(1):99-114.
|
|
[35]KONDO Y,UENO Y,KOBAYASHI K,et al.Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes[J].J Infect Dis,2010,202(2):202-213.
|
|
[36]ALLWEISS L,VOLZ T,LUTGEHETMANN M,et al.Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration[J].J Hepatol,2014,60(3):500-507.
|
|
[37]SADLER AJ,WILLIAMS BR.Interferon-inducible antiviral effectors[J].Nat Rev Immunol,2008,8(7):559-568.
|
|
[38]XU C,GUO H,PAN XB,et al.Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus[J].J Virol,2010,84(18):9332-9340.
|
|
[39]BELLONI L,ALLWEISS L,GUERRIERI F,et al.IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear ccc DNA minichromosome[J].J Clin Invest,2012,122(2):529-537.
|
|
[40]LUCIFORA J,XIA Y,REISINGER F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus ccc DNA[J].Science,2014,343(6176):1221-1228.
|
|
[41]MICCO L,PEPPA D,LOGGI E,et al.Differential boosting of innate and adaptive antiviral responses during pegylated-interferonalpha therapy of chronic hepatitis B[J].J Hepatol,2013,58(2):225-233.
|
|
[42]REHERMANN B,LAU D,HOOFNAGLE JH,et al.Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection[J].J Clin Invest,1996,97(7):1655-1665.
|
|
[43]MARCELLIN P,AHN SH,MA X,et al.Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology,2016,150(1):134-144.
|
|
[44]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigen-positive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723.
|
|
[45]CAREY I,D'ANTIGA L,BANSAL S,et al.Immune and viral profile from tolerance to hepatitis B surface antigen clearance:a longitudinal study of vertically hepatitis B virus-infected children on combined therapy[J].J Virol,2011,85(5):2416-2428.
|
|
[46]de NIET A,STELMA F,JANSEN L,et al.Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy[J].J Hepatol,2016,64(3):539-546.
|
|
[47]BRUDER CJ,DUFEU-DUCHESNE T,LEROY V,et al.Pegylated interferon alpha-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBs Ag seroconversion[J].PLo S One,2016,11(6):e158297.
|
DownLoad: